The Effect of Gut Microbiota-Targeted Interventions on Neuroinflammation and Motor Function in Parkinson’s Disease Animal Models—A Systematic Review
Paul-Ștefan Panaitescu,
No information about this author
Vlad Răzniceanu,
No information about this author
Ștefania-Maria Mocrei-Rebrean
No information about this author
et al.
Current Issues in Molecular Biology,
Journal Year:
2024,
Volume and Issue:
46(5), P. 3946 - 3974
Published: April 26, 2024
Gut
microbiome-targeted
interventions
such
as
fecal
transplant,
prebiotics,
probiotics,
synbiotics,
and
antibiotic
gut
depletion
are
speculated
to
be
of
potential
use
in
delaying
the
onset
progression
Parkinson’s
disease
by
rebalancing
microbiome
context
gut–brain
axis.
Our
study
aims
organize
recent
findings
regarding
these
animal
models
identify
how
they
affect
neuroinflammation
motor
outcomes.
A
systematic
literature
search
was
applied
PubMed,
Web
Science,
Embase,
SCOPUS
for
non-dietary
interventions.
Studies
that
investigated
gut-targeted
using
vivo
murine
PD
follow
dopaminergic
cell
loss,
tests,
neuroinflammatory
markers
outcomes
were
considered
eligible.
total
1335
studies
identified
databases,
out
which
29
found
narrative
systematization
resulting
data
performed,
effect
direction
represented.
Quality
assessment
SYRCLE
risk
bias
tool
also
performed.
Out
eligible
studies,
we
a
significant
majority
report
intervention
reduced
loss
(82.76%,
95%
CI
[64.23%,
94.15%])
produced
induction
model.
Also,
most
reported
reduction
microglial
(87.5%,
[61.65%,
98.45%])
astrocytic
activation
(84,62%,
[54.55%,
98.08%])
caused
These
results
mirrored
(96.4%
[81.65%,
99.91%])
reporting
an
increase
performance
behavioral
tests.
limitation
insufficient
information
assess
specific
causes
bias.
show
can
improve
acute
models.
Further
needed
clarify
if
benefits
transfer
long-term
pathogenesis
disease,
is
not
yet
fully
understood.
The
had
no
funding
source,
protocol
registered
PROSPERO
database
with
ID
number
CRD42023461495.
Language: Английский
Antibiotic Cocktail Exacerbates Esomeprazole-Induced Intestinal Dysmotility While Ameliorating Gastric Dyspepsia in Mice
Antibiotics,
Journal Year:
2025,
Volume and Issue:
14(5), P. 442 - 442
Published: April 27, 2025
Background/Objectives:
Esomeprazole,
a
proton
pump
inhibitor
(PPI),
is
commonly
prescribed
for
gastric-acid-related
disorders
but
has
been
associated
with
impaired
gastrointestinal
(GI)
motility
long-term
use.
However,
the
effect
of
concurrent
antibiotic
administration
on
this
dysfunction
remains
unclear.
Therefore,
study
aimed
to
investigate
effects
antibiotics
esomeprazole-induced
GI
and
explore
underlying
mechanisms
in
mouse
model.
Methods:
Male
C57BL/6
mice
were
orally
administered
esomeprazole
(160
mg/kg)
five
times
per
week
4
weeks.
Three
days
before
initiating
treatment,
broad-spectrum
cocktail
(ABX)
consisting
ampicillin
(1
g/kg),
neomycin
metronidazole
vancomycin
(0.5
g/kg)
was
provided
drinking
water
maintained
throughout
experimental
period.
Mosapride
(3
mg/kg),
prokinetic
agent,
used
as
positive
control.
Results:
Neither
alone
nor
combination
ABX
affected
body
weight
or
food
intake.
Compared
normal
controls,
treatment
significantly
delayed
both
intestinal
transit
gastric
emptying.
co-administration
further
pronounced
time
improved
motility.
The
potential
may
involve
interactions
among
H+/K+-ATPase,
CYP3A11,
hormones
(secretin
motilin),
gut
microbiome.
Conclusions:
Long-term
use
can
impair
motility,
co-treatment
exacerbates
delay
while
paradoxically
enhancing
These
findings
highlight
critical
role
microbiota
suggest
that
should
be
approached
caution,
particularly
when
combined
PPI
therapy.
Language: Английский
Peroxisome Proliferator-Activated Receptors (PPARs) May Mediate the Neuroactive Effects of Probiotic Metabolites: An In Silico Approach
International Journal of Molecular Sciences,
Journal Year:
2025,
Volume and Issue:
26(10), P. 4507 - 4507
Published: May 9, 2025
It
is
well
established
that
the
gut-brain
axis
(GBA)
a
bidirectional
communication
between
gut
and
brain.
This
axis,
critical
in
maintaining
overall
homeostasis,
regulated
at
neuronal,
endocrine,
immunological
levels,
all
of
which
may
be
influenced
by
microbiota
(GM).
Therefore,
dysbiosis
or
disruption
GM
have
serious
consequences
including
neuroinflammation
due
to
overactivation
immune
system.
Strategies
reestablish
integrity
via
use
probiotics
are
being
pursued
as
novel
therapeutic
intervention
variety
central
peripheral
diseases.
The
mechanisms
leading
efficacy
probiotics,
however,
not
fully
evident.
Here,
we
performed
computational
analysis
on
two
major
namely
Lactobacillus
Lacticaseibacillus
rhamnosus
GG
(formerly
named
rhamnosus,
L.
GG)
Bifidobacterium
animalis
spp.
lactis
(B.
B.
animalis)
only
shed
some
light
their
mechanism(s)
action
but
also
identify
potential
molecular
targets
for
probiotics.
Using
PubMed
web
page
BioCyc
Database
Collection
platform
specifically
analyzed
proteins
affected
metabolites
these
bacteria.
Our
results
indicate
peroxisome
proliferator-activated
receptors
(PPARs),
nuclear
receptor
involved
regulation
inflammation
key
mediators
neuroactive
effect
Language: Английский
Exploring the Frontiers of Neuroinflammation: New Horizons in Research and Treatment
Current Issues in Molecular Biology,
Journal Year:
2024,
Volume and Issue:
46(10), P. 11665 - 11667
Published: Oct. 19, 2024
The
Special
Issue
"
Language: Английский
The Role of the Gastrointestinal Microbiota in Parkinson’s Disease
Biomolecules,
Journal Year:
2024,
Volume and Issue:
15(1), P. 26 - 26
Published: Dec. 28, 2024
Background/Objectives:
Parkinson’s
disease
(PD)
is
a
progressive
neurodegenerative
disorder
characterized
by
the
loss
of
dopaminergic
neurons
leading
to
debilitating
motor
and
non-motor
symptoms.
Beyond
its
well-known
neurological
features,
emerging
evidence
underscores
pivotal
role
gut–brain
axis
gastrointestinal
microbiota
in
PD
pathogenesis.
Dysbiosis
has
been
strongly
linked
associated
with
increased
intestinal
permeability,
chronic
inflammation,
production
neurotoxic
metabolites
that
may
exacerbate
neuronal
damage.
Methods:
This
review
delves
into
complex
interplay
between
dysbiosis,
shedding
light
on
two
peculiar
subsets
Helicobacter
pylori
infection
small-intestinal
bacterial
overgrowth.
These
conditions
not
only
contribute
progression
but
also
influence
therapeutic
responses
such
as
L-dopa
efficacy.
Conclusions:
The
potential
modulate
gut
through
probiotics,
prebiotics,
synbiotics;
fecal
transplantation;
antibiotics
represents
promising
frontier
for
innovative
treatments.
Despite
this
potential,
current
limited
small
sample
sizes
methodological
variability
across
studies.
Rigorous,
large-scale,
randomized
placebo-controlled
trials
standardized
treatments
terms
composition,
dosage,
duration
are
urgently
needed
validate
these
findings
pave
way
microbiota-based
strategies
management.
Language: Английский